Volume 4, Issue 2 (Vol.4 No.2 Apr 2016)                   rbmb.net 2016, 4(2): 89-97 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Moradi B, Sankian M, Amini Y, Meshkat Z. Construction of a Novel DNA Vaccine Candidate Encoding an HspX-PPE44-EsxV Fusion Antigen of Mycobacterium tuberculosis. rbmb.net. 2016; 4 (2) :89-97
URL: http://rbmb.net/article-1-76-en.html
Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract:   (4685 Views)

Background: Mycobacterium tuberculosis is the causative agent of tuberculosis (TB). Bacille Calmette-Guerin (BCG) vaccine, is not effective in adults, therefore, many efforts have been made to produce an effective adult TB vaccine. The aim of this study was to develop a new tuberculosis DNA vaccine candidate encoding a recombinant HspX-PPE44-EsxV fusion antigen of M. tuberculosis.

Methods: A fusion DNA segment consisting of HspX, linker, PPE44, linker, and EsxV, after codon optimization, was designed. The fusion DNA was cloned and its sequence confirmed. Then, expression of a recombinant pcDNA3.1 (+)/HspX-PPE44-EsxV plasmid in Chinese hamster ovary (CHO) cells was verified by RT-PCR and Western-blot analysis.

Results: A 1968 bp band in RT-PCR and a 68 kDa band on Western-blot analysis confirmed transcription and expression of recombinant hspX-ppe44-esxV in eukaryotic cells.

Conclusions: A recombinant DNA segment encoding the HspX-PPE44-EsxV fusion antigen of M. tuberculosis was constructed and considered to be tested as a new TB DNA vaccine candidate.

Full-Text [PDF 605 kb]   (1350 Downloads)    
Subject: Molecular Biology
Received: 2015/12/5 | Accepted: 2016/01/12 | Published: 2016/04/30

Add your comments about this article : Your username or Email:

Send email to the article author

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb